Literature DB >> 18795474

Novel combination strategies to repair the injured mammalian spinal cord.

Mary Bartlett Bunge1.   

Abstract

Due to the varied and numerous changes in spinal cord tissue following injury, successful treatment for repair may involve strategies combining neuroprotection (pharmacological prevention of some of the damaging intracellular cascades that lead to secondary tissue loss), axonal regeneration promotion (cell transplantation, genetic engineering to increase growth factors, neutralization of inhibitory factors, reduction in scar formation), and rehabilitation. Our goal has been to find effective combination strategies to improve outcome after injury to the adult rat thoracic spinal cord. Combination interventions tested have been implantation of Schwann cells (SCs) plus neuroprotective agents and growth factors administered in various ways, olfactory ensheathing cell (OEC) implantation, chondroitinase addition, or elevation of cyclic AMP. The most efficacious strategy in our hands for the acute complete transection/SC bridge model, including improvement in locomotion [Basso, Beattie, Bresnahan Scale (BBB)], is the combination of SCs, OECs, and chondroitinase administration (BBB 2.1 vs 6.6, 3 times more myelinated axons in the SC bridge, increased serotonergic axons in the bridge and beyond, and significant correlation between the number of bridge myelinated axons and functional improvement). We found the most successful combination strategy for a subacute spinal cord contusion injury (12.5-mm, 10-g weight, MASCIS impactor) to be SCs and elevation of cyclic AMP (BBB 10.4 vs 15, significant increases in white matter sparing, in myelinated axons in the implant, and in responding reticular formation and red and raphe nuclei, and a significant correlation between the number of serotonergic fibers and improvement in locomotion). Thus, in two injury paradigms, these combination strategies as well as others studied in our laboratory have been found to be more effective than SCs alone and suggest ways in which clinical application may be developed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18795474      PMCID: PMC2565567          DOI: 10.1080/10790268.2008.11760720

Source DB:  PubMed          Journal:  J Spinal Cord Med        ISSN: 1079-0268            Impact factor:   1.985


  37 in total

1.  Combining Schwann cell bridges and olfactory-ensheathing glia grafts with chondroitinase promotes locomotor recovery after complete transection of the spinal cord.

Authors:  Karim Fouad; Lisa Schnell; Mary B Bunge; Martin E Schwab; Thomas Liebscher; Damien D Pearse
Journal:  J Neurosci       Date:  2005-02-02       Impact factor: 6.167

Review 2.  Olfactory ensheathing cells and spinal cord repair.

Authors:  Alan Mackay-Sim
Journal:  Keio J Med       Date:  2005-03

3.  Bridging Schwann cell transplants promote axonal regeneration from both the rostral and caudal stumps of transected adult rat spinal cord.

Authors:  X M Xu; A Chen; V Guénard; N Kleitman; M B Bunge
Journal:  J Neurocytol       Date:  1997-01

4.  Long-distance axonal regeneration in the transected adult rat spinal cord is promoted by olfactory ensheathing glia transplants.

Authors:  A Ramón-Cueto; G W Plant; J Avila; M B Bunge
Journal:  J Neurosci       Date:  1998-05-15       Impact factor: 6.167

5.  Axonal regeneration into Schwann cell-seeded guidance channels grafted into transected adult rat spinal cord.

Authors:  X M Xu; V Guénard; N Kleitman; M B Bunge
Journal:  J Comp Neurol       Date:  1995-01-02       Impact factor: 3.215

6.  Nerve growth factor-hypersecreting Schwann cell grafts augment and guide spinal cord axonal growth and remyelinate central nervous system axons in a phenotypically appropriate manner that correlates with expression of L1.

Authors:  N Weidner; A Blesch; R J Grill; M H Tuszynski
Journal:  J Comp Neurol       Date:  1999-11-01       Impact factor: 3.215

7.  A combination of BDNF and NT-3 promotes supraspinal axonal regeneration into Schwann cell grafts in adult rat thoracic spinal cord.

Authors:  X M Xu; V Guénard; N Kleitman; P Aebischer; M B Bunge
Journal:  Exp Neurol       Date:  1995-08       Impact factor: 5.330

8.  Methylprednisolone administration improves axonal regeneration into Schwann cell grafts in transected adult rat thoracic spinal cord.

Authors:  A Chen; X M Xu; N Kleitman; M B Bunge
Journal:  Exp Neurol       Date:  1996-04       Impact factor: 5.330

9.  Schwann cells genetically modified to secrete human BDNF promote enhanced axonal regrowth across transected adult rat spinal cord.

Authors:  P Menei; C Montero-Menei; S R Whittemore; R P Bunge; M B Bunge
Journal:  Eur J Neurosci       Date:  1998-02       Impact factor: 3.386

10.  Grafts of genetically modified Schwann cells to the spinal cord: survival, axon growth, and myelination.

Authors:  M H Tuszynski; N Weidner; M McCormack; I Miller; H Powell; J Conner
Journal:  Cell Transplant       Date:  1998 Mar-Apr       Impact factor: 4.139

View more
  51 in total

1.  Differing Schwann cells and olfactory ensheathing cells behaviors, from interacting with astrocyte, produce similar improvements in contused rat spinal cord's motor function.

Authors:  Bing Cang Li; Chuan Xu; Jie Yuan Zhang; Yue Li; Zhao Xia Duan
Journal:  J Mol Neurosci       Date:  2012-03-11       Impact factor: 3.444

2.  Astrocyte-produced ephrins inhibit schwann cell migration via VAV2 signaling.

Authors:  Fardad T Afshari; Jessica C Kwok; James W Fawcett
Journal:  J Neurosci       Date:  2010-03-24       Impact factor: 6.167

3.  Neuroprotective effect of bone marrow stromal cell combination with atorvastatin in rat model of spinal cord injury.

Authors:  Fang Li; Dan Fei; Libo Sun; Sixun Zhang; Yue Yuan; Li Zhang; Kuiming Zhao; Rui Li; Yanbing Yu
Journal:  Int J Clin Exp Med       Date:  2014-12-15

4.  Soluble epoxide hydrolase inhibition provides multi-target therapeutic effects in rats after spinal cord injury.

Authors:  Xiaojing Chen; Xiaoqi Chen; Xiaojiang Huang; Chuan Qin; Yongkang Fang; Yang Liu; Guibing Zhang; Dengji Pan; Wei Wang; Minjie Xie
Journal:  Mol Neurobiol       Date:  2015-02-10       Impact factor: 5.590

Review 5.  Combination treatment with chondroitinase ABC in spinal cord injury--breaking the barrier.

Authors:  Rong-Rong Zhao; James W Fawcett
Journal:  Neurosci Bull       Date:  2013-07-09       Impact factor: 5.203

6.  Combined effects of rat Schwann cells and 17β-estradiol in a spinal cord injury model.

Authors:  Zeinab Namjoo; Fateme Moradi; Roya Aryanpour; Abbas Piryaei; Mohammad Taghi Joghataei; Yusef Abbasi; Amir Hosseini; Sajad Hassanzadeh; Fatemeh Ranjbar Taklimie; Cordian Beyer; Adib Zendedel
Journal:  Metab Brain Dis       Date:  2018-04-15       Impact factor: 3.584

Review 7.  Translational spinal cord injury research: preclinical guidelines and challenges.

Authors:  Paul J Reier; Michael A Lane; Edward D Hall; Y D Teng; Dena R Howland
Journal:  Handb Clin Neurol       Date:  2012

8.  Bridging defects in chronic spinal cord injury using peripheral nerve grafts combined with a chitosan-laminin scaffold and enhancing regeneration through them by co-transplantation with bone-marrow-derived mesenchymal stem cells: case series of 14 patients.

Authors:  Sherif M Amr; Ashraf Gouda; Wael T Koptan; Ahmad A Galal; Dina Sabry Abdel-Fattah; Laila A Rashed; Hazem M Atta; Mohammad T Abdel-Aziz
Journal:  J Spinal Cord Med       Date:  2013-11-26       Impact factor: 1.985

9.  A novel growth-promoting pathway formed by GDNF-overexpressing Schwann cells promotes propriospinal axonal regeneration, synapse formation, and partial recovery of function after spinal cord injury.

Authors:  Ling-Xiao Deng; Ping Deng; Yiwen Ruan; Zao Cheng Xu; Nai-Kui Liu; Xuejun Wen; George M Smith; Xiao-Ming Xu
Journal:  J Neurosci       Date:  2013-03-27       Impact factor: 6.167

10.  Fabrication of growth factor- and extracellular matrix-loaded, gelatin-based scaffolds and their biocompatibility with Schwann cells and dorsal root ganglia.

Authors:  Rodolfo E Gámez Sazo; Katsumi Maenaka; Weiyong Gu; Patrick M Wood; Mary Bartlett Bunge
Journal:  Biomaterials       Date:  2012-08-17       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.